Stock Fundamentals

Company Information

Company Name
Cullinan Oncology LLC
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US2300311063
CIK: 0001789972
CUSIP: 230031106
Currency: USD
Full Time Employees: 109
Phone: 617 410 4650
Fiscal Year End: December
IPO Date: Jan 08, 2021
Description:

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Address:

One Main Street, Cambridge, MA, United States, 02142

Directors & Officers

Name Title Year Born
Mr. Nadim Ahmed M.S. President, CEO & Director 1968
Ms. Mary Kay Fenton CPA Chief Financial Officer 1964
Dr. Jeffrey Jones M.B.A., M.D., M.P.H. Chief Medical Officer 1971
Dr. Patrick A. Baeuerle Ph.D. Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board 1958
Dr. Jennifer Michaelson Ph.D. Chief Scientific Officer 1967
Nicholas Smith Head of Investor Relations NA
Ms. Jacquelyn L. Sumer J.D. Chief Legal Officer, Chief Compliance Officer & Corporate Secretary 1978
Mr. Steve Andre Chief Human Resources Officer NA
Dr. Corinne Savill Ph.D. Chief Business Officer 1959
Ms. Rose Weldon Senior Vice President of Corporate Affairs NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 05, 2026 Jennifer Michaelson N/A Sale 8.00K $15.68 $125.44K
Feb 25, 2026 Jennifer Michaelson N/A Sale 1.78K $14.14 $25.17K
Feb 24, 2026 Jacquelyn L Sumer N/A Sale 3.60K $14.47 $52.11K
Feb 24, 2026 Jeffrey Alan Jones N/A Sale 4.58K $14.47 $66.30K
Feb 24, 2026 Jennifer Michaelson N/A Sale 3.60K $14.47 $52.11K
Feb 24, 2026 Nadim Ahmed N/A Sale 13.52K $14.47 $195.56K
Feb 23, 2026 Jennifer Michaelson N/A Sale 1.75K $13.99 $24.51K
Feb 20, 2026 Jacquelyn L Sumer N/A Sale 3.74K $13.62 $50.97K
Feb 20, 2026 Jeffrey Alan Jones N/A Sale 4.98K $13.62 $67.85K
Feb 20, 2026 Jennifer Michaelson N/A Sale 11.74K $14.08 $165.33K
Feb 20, 2026 Mary Kay Fenton N/A Sale 4.40K $13.62 $59.90K
Feb 20, 2026 Nadim Ahmed N/A Sale 16.38K $13.62 $223.11K
Feb 12, 2026 Jennifer Michaelson N/A Sale 416.00 $12.03 $5.00K
Jan 22, 2026 Jennifer Michaelson N/A Sale 4.00K $12.30 $49.20K
Dec 23, 2025 Nadim Ahmed N/A Sale 9.92K $10.01 $99.32K
Dec 19, 2025 Jennifer Michaelson N/A Sale 1.35K $10.01 $13.46K
Dec 18, 2025 Jacquelyn L Sumer N/A Sale 3.48K $9.67 $33.65K
Dec 18, 2025 Jeffrey Alan Jones N/A Sale 4.63K $9.67 $44.79K
Dec 18, 2025 Jennifer Michaelson N/A Sale 2.90K $9.67 $28.02K
Dec 15, 2025 Jennifer Michaelson N/A Sale 995.00 $11.90 $11.84K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Lynx1 Capital Management, LP 8.96M Mar 31, 2026 14.58% $20.13 0.00%
MPM Oncology Impact Management LP 7.65M Mar 31, 2026 12.44% $8.39 0.00%
Bvf Inc 5.75M Mar 31, 2026 9.36% $2.60 0.00%
BlackRock Inc 4.45M Mar 31, 2026 7.24% $0.00 1.13%
Vanguard Group Inc 3.30M Dec 31, 2025 5.37% $0.00 12.07%
Kynam Capital Management, LP 3.11M Mar 31, 2026 5.07% $2.73 0.00%
State Street Corp 2.54M Mar 31, 2026 4.14% $0.00 15.78%
Vanguard Capital Management, LLC 2.48M Mar 31, 2026 4.04% $0.00 0.00%
T. Rowe Price Associates, Inc. 2.03M Mar 31, 2026 3.30% $0.00 4,201.44%
Blue Owl Capital Holdings LP 1.91M Mar 31, 2026 3.11% $7.29 -18.77%
RTW INVESTMENTS, LLC 1.71M Mar 31, 2026 2.78% $0.24 0.00%
VR Adviser, LLC 1.38M Mar 31, 2026 2.25% $0.73 0.00%
Geode Capital Management, LLC 1.37M Mar 31, 2026 2.23% $0.00 5.07%
Siren, L.L.C. 1.19M Mar 31, 2026 1.94% $0.47 0.00%
Nextech Invest, Ltd. 1.14M Dec 31, 2025 1.86% $1.14 0.00%
BOOTHBAY FUND MANAGEMENT, LLC 1.11M Mar 31, 2026 1.81% $0.21 -10.04%
Marshall Wace Asset Management Ltd 1.05M Mar 31, 2026 1.71% $0.01 153.30%
Dimensional Fund Advisors, Inc. 906.03K Mar 31, 2026 1.47% $0.00 6.75%
Point72 Asset Management, L.P. 905.38K Mar 31, 2026 1.47% $0.02 151.38%
Nuveen, LLC 805.70K Mar 31, 2026 1.31% $0.00 39.13%

Shares Statistics

Shares Outstanding: 61.46M
Shares Float: 44.15M
% Insiders: 44.50%
% Institutions: 10,771.00%
Short % Float: 24.47%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 1.86M 3.02% ▲ 0.00% Apr 30, 2026
2 State Street® SPDR® S&P® Biotech ETF 1.45M 2.35% ▼ 0.61% May 31, 2026
3 iShares Russell 2000 ETF 1.29M 2.10% ▲ 0.93% May 29, 2026
4 T. Rowe Price New Horizons 818.26K 1.33% ▲ 92.97% Apr 30, 2026
5 Vanguard Institutional Extnd Mkt Idx Tr 579.10K 0.94% ▲ 1.56% Apr 30, 2026
6 Fidelity Small Cap Index 529.91K 0.86% ▲ 0.21% Mar 31, 2026
7 iShares Russell 2000 Value ETF 468.15K 0.76% ▲ 0.00% May 29, 2026
8 Nuveen Quant Small Cap Equity R6 463.24K 0.75% ▲ 0.00% Apr 30, 2026
9 US Small-Cap Growth II Equity Comp 424.03K 0.69% ▲ 0.00% Mar 31, 2026
10 Russell 2000 Equity Index Fund B 336.16K 0.55% ▲ 0.00% Dec 31, 2025

Valuation Metrics

Enterprise Value: $764.73M
Trailing P/E: 0.00
Forward P/E: 6.74

Financial Highlights

Market Cap: $1.11B
EBITDA: $-240.04M
Book Value: $5.96
Earnings/Share: $-3.37
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -30.57%
ROE (TTM): -48.16%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 10.25x 0.00x 0.09x N/A 0.00x
2024-12-31 13.53x 0.00x 0.05x N/A -0.01x
2023-12-31 17.07x 0.00x 0.06x N/A -0.01x
2022-12-31 21.09x 0.00x 0.05x 0.26x -0.01x
2021-12-31 25.25x 0.00x 0.03x -1.04x 0.00x
2020-12-31 14.82x 0.00x 0.07x -67.94x 0.00x
2019-12-31 39.67x 0.00x 1.40x N/A 0.00x
2018-12-31 25.85x 0.00x 1.60x N/A 0.00x
2016-12-31 0.01x -1.15x 168.35x N/A -3.35x
2015-12-31 0.00x -1.75x 10,550.14x N/A -22.80x
2014-12-31 0.07x -1.88x 70.47x N/A -16.56x
2013-12-31 0.23x -1.94x 45.18x N/A -2.78x
2012-12-31 0.00x 0.00x 32.30x N/A N/A

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CGEM.US!